What are the treatment implications for use of PARP inhibitors in patients with metastatic triple negative breast cancer with a germline vs somatic BRCA muation?
Answer from: Medical Oncologist at Academic Institution
To date, we only have results supporting the use of PARP inhibitors in breast cancer patients with germline BRCA1/2 mutations and advanced HER2 negative breast cancer. Studies are being initiated to explore the use in breast cancers harboring somatic mutations (NCT03990896). Enrollment in thes...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I would use a parp inhibitor for either as part of our rx armamentarium
Comments
Medical Oncologist at Siri Onclogy and hematology Infusion Service
I agree with the above comment. There is no differ...
I agree with the above comment. There is no differ...